TTNP insider filings
TITAN PHARMACEUTICALS INC — 30 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-10-08. Screen TTNP transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for TTNP between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — TITAN PHARMACEUTICALS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-10-08 | 4 | Ben-Tzvi Avraham — Director | Disposition to issuer (D): 3,313 · Disposition to issuer (D): 1,250 (derivative) · Disposition to issuer (D): 5,000 (derivative) | EDGAR |
| 2024-03-27 | 4 | Choong Choon Hau — 10% owner | Conversion (C): 54,132 @ $0 · Conversion (C) @ $0 | EDGAR |
| 2023-10-26 | 4 | Ben-Tzvi Avraham — Director | Grant/award (A): 16,250 @ $0 | EDGAR |
| 2023-10-26 | 4 | Greenberg Eric Howard — Director | Grant/award (A): 16,250 @ $0 | EDGAR |
| 2023-10-26 | 4 | McMurdo Matthew Charles — Director | Grant/award (A): 16,250 @ $0 | EDGAR |
| 2023-10-26 | 4 | Beebe Katherine — President and COO, Director | Grant/award (A): 16,250 @ $0 | EDGAR |
| 2023-10-26 | 4 | NATAN DAVID — Director | Grant/award (A): 16,250 @ $0 | EDGAR |
| 2023-07-31 | 4 | Ben-Tzvi Avraham — Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-07-31 | 4 | Greenberg Eric Howard — Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-07-31 | 4/A | Chasey Peter Louis — Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-07-31 | 4/A | McMurdo Matthew Charles — Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-07-31 | 4 | Lazar David E. — Chief Executive Officer, Director | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2023-07-31 | 4/A | NATAN DAVID — Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | Chasey Peter Louis — Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | McMurdo Matthew Charles — Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | Beebe Katherine — President and COO, Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | NATAN DAVID — Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-06-28 | 4/A | Lazar David E. — Chief Executive Officer, Director, 10% owner Activist Investing LLC | Sale (S): 3,388,902 @ $1.23 · Sale (S): 359,066 @ $1.23 | EDGAR |
| 2023-06-23 | 4 | Lazar David E. — Chief Executive Officer, Director, 10% owner Activist Investing LLC | Sale (S): 3,388,902 @ $1.23 · Sale (S): 359,066 @ $1.23 | EDGAR |
| 2023-01-26 | 4 | Lazar David E. — Chief Executive Officer, Director, 10% owner Activist Investing LLC | Purchase (P): 37,500 @ $0.97 · Purchase (P): 20,000 @ $1.00 | EDGAR |
| 2022-07-08 | 4 | Lazar David E. — 10% owner Activist Investing LLC | Purchase (P): 1,165,975 @ $0.77 · Purchase (P): 744,294 @ $0.99 · Purchase (P): 315,921 @ $0.89 | EDGAR |
| 2022-01-28 | 4 | MCNAB JAMES R — Director | Other (J): 51,021 | EDGAR |
| 2022-01-05 | 4 | Beebe Katherine — President and COO, Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Rubin Marc — Executive Chairman, Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Akers Joseph A — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | MCNAB JAMES R — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-02-11 | 4 | Beebe Katherine — President and COO, Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-02-11 | 4 | Rubin Marc — Executive Chairman, Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-02-11 | 4 | Akers Joseph A — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-02-11 | 4 | MCNAB JAMES R — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — TITAN PHARMACEUTICALS INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-10-01 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-26 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-02 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-08 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-06 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TTNP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs